Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
131.95
+3.95 (3.09%)
At close: Aug 1, 2025, 4:00 PM
132.45
+0.50 (0.38%)
After-hours: Aug 1, 2025, 7:58 PM EDT
bluebird bio Stock Forecast
Stock Price Forecast
The 23 analysts that cover bluebird bio stock have a consensus rating of "Buy" and an average price target of $187.96, which forecasts a 42.45% increase in the stock price over the next year. The lowest target is $115 and the highest is $292.
Price Target: $187.96 (+42.45%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for bluebird bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 14 | 15 | 15 | 16 | 16 | 16 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 28 | 27 | 27 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $125 → $135 | Hold | Maintains | $125 → $135 | +2.31% | Aug 1, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $208 → $219 | Buy | Maintains | $208 → $219 | +65.97% | Aug 1, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $146 → $144 | Hold | Maintains | $146 → $144 | +9.13% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $187 → $194 | Strong Buy | Maintains | $187 → $194 | +47.03% | Aug 1, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $213 | Buy | Reiterates | $213 | +61.42% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
9.45B
from 9.68B
Decreased by -2.36%
Revenue Next Year
9.25B
from 9.45B
Decreased by -2.09%
EPS This Year
15.27
from 11.18
Increased by 36.56%
EPS Next Year
15.74
from 15.27
Increased by 3.12%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.1B | 10.2B | 10.4B | ||
| Avg | 9.4B | 9.3B | 9.3B | ||
| Low | 8.9B | 8.2B | 8.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.9% | 7.6% | 12.4% | ||
| Avg | -2.4% | -2.1% | 1.0% | ||
| Low | -8.1% | -13.2% | -11.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.70 | 18.82 | 20.61 | ||
| Avg | 15.27 | 15.74 | 16.63 | ||
| Low | 14.04 | 12.48 | 12.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.3% | 23.2% | 30.9% | ||
| Avg | 36.6% | 3.1% | 5.6% | ||
| Low | 25.6% | -18.3% | -19.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.